SEARCH:   Advanced

Blood, 15 December 2005, Vol. 106, No. 13, pp. 4152-4158. Prepublished online as a Blood First Edition Paper on September 6, 2005; DOI 10.1182/blood-2005-05-2048. This Article Full Text (PDF) All Versions of this Article: 2005-05-2048v1 106/13/4152    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Male, C. Articles by Mitchell, L. Search for Related Content PubMed PubMed Citation Articles by Male, C. Articles by Mitchell, L. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted May 23, 2005 Accepted July 29, 2005 Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus Christoph Male, Denise Foulon, Hugh Hoogendoorn, Patricia Vegh, Earl Silverman, Michele David, and Lesley Mitchell* Children's Hospital, Medical University of Vienna, Vienna, Austria; Henderson Research Centre, McMaster University, Hamilton, Ontario, Canada Henderson Research Centre, McMaster University, Hamilton, Ontario, Canada Hospital for Sick Children, Toronto, Ontario, Canada Hospital Ste. Justine, Montreal, Quebec, Canada Stollery Children's Hospital, Edmonton, Alberta, Canada * Corresponding author; email: lesleymitchell{at}cha.ab.ca. Study objectives were to determine in children with systemic lupus erythematosus (SLE) the: i) association of antiphosholipid antibody (APLA) subtypes with thrombotic events (TE); ii) predictive value of persistent versus transient antibodies for TE. Cohort study of 58 SLE children in whom lupus anticoagulants (LA), anticardiolipin antibodies (ACLA), anti-2-glycoprotein-I (anti-2GPI), anti-prothrombin (anti-PT) were assessed on 2 occasions ( >3 months apart). Antibodies were classified as persistent (positive 2 occasions) or transient (positive once). Outcomes were symptomatic TE, confirmed by objective radiographic tests identified retrospectively and prospectively. Seven of 58 patients (12%) had 10 TE; 5 patients had TE during prospective follow-up. Persistent LA showed the strongest association with TE (p< 0.0001). Persistent ACLA (p=0.003) and anti-2GPI (p=0.002) were significantly associated with TE, anti-PT (p=0.063) showed a trend. Persistent or transient LA and anti-2GPI showed similar strength of association, while ACLA and anti-PT were no longer associated with TE. Positivity for multiple APLA subtypes showed stronger associations with TE than for individual APLA subtypes because of improved specificity. Lupus anticoagulant is the strongest predictor of the risk of TE, other APLA subtypes provide no additional diagnostic value. Anticardiolipin antibodies and anti-PT require serial testing, as only persistent antibodies are associated with TE. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. J. Hobbs, G.-M. Barletta, J. S. Rajpal, M. N. Rajpal, D. P. Weismantel, J. D. Birmingham, and T. E. Bunchman Severe paediatric systemic lupus erythematosus nephritis--a single centre experience Nephrol. Dial. Transplant., September 15, 2009; (2009) gfp481v1. [Abstract] [Full Text] [PDF] E. Descloux, I. Durieu, P. Cochat, D. Vital-Durand, J. Ninet, N. Fabien, and R. Cimaz Influence of age at disease onset in the outcome of paediatric systemic lupus erythematosus Rheumatology, July 1, 2009; 48(7): 779 - 784. [Abstract] [Full Text] [PDF] J. Dhar, J Andersen, L Essenmacher, J Ager, G Bentley, and R. Sokol Thrombophilic patterns of coagulation factors in lupus Lupus, April 1, 2009; 18(5): 400 - 406. [Abstract] [PDF] G. W. Moore, S. Rangarajan, and G. F. Savidge The Activated Seven Lupus Anticoagulant Assay Detects Clinically Significant Antibodies Clinical and Applied Thrombosis/Hemostasis, July 1, 2008; 14(3): 332 - 337. [Abstract] [PDF] P. Monagle, E. Chalmers, A. Chan, G. deVeber, F. Kirkham, P. Massicotte, and A. D. Michelson Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 887S - 968S. [Abstract] [Full Text] [PDF] E. Descloux, I. Durieu, P. Cochat, D. Vital Durand, J. Ninet, N. Fabien, and R. Cimaz Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies Rheumatology, February 1, 2008; 47(2): 183 - 187. [Abstract] [Full Text] [PDF] A. Martinez-Berriotxoa, G. Ruiz-Irastorza, M.-V. Egurbide, M. Garmendia, J. Gabriel Erdozain, I. Villar, and C. Aguirre Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus Lupus, October 1, 2007; 16(10): 810 - 816. [Abstract] [PDF] T. Avcin and E. Silverman Review: Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome Lupus, August 1, 2007; 16(8): 627 - 633. [Abstract] [PDF] S. M. Abo and V. A. DeBari Laboratory Evaluation of the Antiphospholipid Syndrome Ann. Clin. Lab. Sci., January 1, 2007; 37(1): 3 - 14. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020